BRIEF-Polyrizon Completes FDA Pre-Submission Meeting For PL-14 Allergy Blocker Nasal Spray

Reuters12-08

Dec 8 (Reuters) - Polyrizon Ltd PLRZ.O:

POLYRIZON COMPLETES FDA PRE-SUBMISSION MEETING FOR PL-14 ALLERGY BLOCKER NASAL SPRAY

Source text: ID:nGNX40WlNT

Further company coverage: PLRZ.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589335638?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 21:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589335638","market":"fut","top_or_hot":-1,"title":"BRIEF-Polyrizon Completes FDA Pre-Submission Meeting For PL-14 Allergy Blocker Nasal Spray","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Polyrizon Completes FDA Pre-Submission Meeting For PL-14 Allergy Blocker Nasal Spray</title></head><body><p><span>Dec 8 (Reuters)</span><span> - </span>Polyrizon Ltd <span>PLRZ.O</span>:</p><ul><li><p>POLYRIZON COMPLETES FDA PRE-SUBMISSION MEETING FOR PL-14 ALLERGY BLOCKER NASAL SPRAY</p></li></ul><p>Source text: <span>ID:nGNX40WlNT</span></p><p>Further company coverage: <span>PLRZ.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Polyrizon Completes FDA Pre-Submission Meeting For PL-14 Allergy Blocker Nasal Spray</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Polyrizon Completes FDA Pre-Submission Meeting For PL-14 Allergy Blocker Nasal Spray\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-08 21:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Polyrizon Completes FDA Pre-Submission Meeting For PL-14 Allergy Blocker Nasal Spray</title></head><body><p><span>Dec 8 (Reuters)</span><span> - </span>Polyrizon Ltd <span>PLRZ.O</span>:</p><ul><li><p>POLYRIZON COMPLETES FDA PRE-SUBMISSION MEETING FOR PL-14 ALLERGY BLOCKER NASAL SPRAY</p></li></ul><p>Source text: <span>ID:nGNX40WlNT</span></p><p>Further company coverage: <span>PLRZ.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PLRZ","symbol_name":"Polyrizon Ltd.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nTUA1RNWVZ:1","article_id":"2589335638","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589335638","pubTimestamp":1765202176,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Polyrizon Completes FDA Pre-Submission Meeting For PL-14 Allergy Blocker Nasal SprayDec 8 (Reuters) - Polyrizon Ltd PLRZ.O:POLYRIZON COMPLETES FDA PRE-SUBMISSION MEETING FOR PL-14 ALLERGY BLOCKE","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PLRZ":"Polyrizon Ltd."},"translate_title":"简介-Polyrizon完成PL-14过敏阻断剂鼻喷雾剂的FDA预提交会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PLRZ":0.9},"content_text":"BRIEF-Polyrizon Completes FDA Pre-Submission Meeting For PL-14 Allergy Blocker Nasal SprayDec 8 (Reuters) - Polyrizon Ltd PLRZ.O:POLYRIZON COMPLETES FDA PRE-SUBMISSION MEETING FOR PL-14 ALLERGY BLOCKER NASAL SPRAYSource text: ID:nGNX40WlNTFurther company coverage: PLRZ.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589335638","isCrawlerRequest":true}